Recherche (Nouvelles)

Bristol Myers Squibb bets US$15.2B on Hengrui partnership to accelerate global drug pipeline

english business top health

Hengrui will oversee the initial human clinical studies for the immunology assets licensed from BMS, a move intended to speed up proof-of-concept data generation.
2026-05-12 21:28:00